Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.

12 In this study using samples collected in a prospective multicenter study, we further validated that patients with higher peritransplantation alemtuzumab levels had an increased risk of MC and impending or established secondary GF; although the latter did not reach statistical significance likely because of the small sample size.

also in 111,027 other papers